Search

Your search keyword '"Marchetti, Ivo"' showing total 6 results
Start Over Author "Marchetti, Ivo" Publication Year Range Last 10 years
6 results on '"Marchetti, Ivo"'

1. ANKRD44 Gene Silencing: A Putative Role in Trastuzumab Resistance in Her2-Like Breast Cancer

Author

La Ferla, Marco, primary, Lessi, Francesca, additional, Aretini, Paolo, additional, Pellegrini, Davide, additional, Franceschi, Sara, additional, Tantillo, Elena, additional, Menicagli, Michele, additional, Marchetti, Ivo, additional, Scopelliti, Claudia, additional, Civita, Prospero, additional, De Angelis, Claudia, additional, Diodati, Lucrezia, additional, Bertolini, Ilaria, additional, Roncella, Manuela, additional, McDonnell, Liam A., additional, Hochman, Jacob, additional, Del Re, Marzia, additional, Scatena, Cristian, additional, Naccarato, Antonio G., additional, Fontana, Andrea, additional, and Mazzanti, Chiara M., additional

Published
2019
Full Text
View/download PDF

2. Loss of c-KIT expression in thyroid cancer cells

Author

Franceschi, Sara, primary, Lessi, Francesca, additional, Panebianco, Federica, additional, Tantillo, Elena, additional, La Ferla, Marco, additional, Menicagli, Michele, additional, Aretini, Paolo, additional, Apollo, Alessandro, additional, Naccarato, Antonio Giuseppe, additional, Marchetti, Ivo, additional, and Mazzanti, Chiara Maria, additional

Published
2017
Full Text
View/download PDF

4. Human saliva as route of inter-human infection for mouse mammary tumor virus

Author

Mazzanti, Chiara Maria, primary, Lessi, Francesca, additional, Armogida, Ivana, additional, Zavaglia, Katia, additional, Franceschi, Sara, additional, Al Hamad, Mohammad, additional, Roncella, Manuela, additional, Ghilli, Matteo, additional, Boldrini, Antonio, additional, Aretini, Paolo, additional, Fanelli, Giovanni, additional, Marchetti, Ivo, additional, Scatena, Cristian, additional, Hochman, Jacob, additional, Naccarato, Antonio Giuseppe, additional, and Bevilacqua, Generoso, additional

Published
2015
Full Text
View/download PDF

5. Break–apart interphase fluorescence in situ hybridization assay in papillary thyroid carcinoma: on the road to optimizing the cut-off level for RET/PTC rearrangements

Author

Colato, Chiara, primary, Vicentini, Caterina, additional, Cantara, Silvia, additional, Pedron, Serena, additional, Brazzarola, Paolo, additional, Marchetti, Ivo, additional, Di Coscio, Giancarlo, additional, Chilosi, Marco, additional, Brunelli, Matteo, additional, Pacini, Furio, additional, and Ferdeghini, Marco, additional

Published
2015
Full Text
View/download PDF

6. ANKRd44 gene silencing: a putative role in trastuzumab resistance in HER2-like breast cancer

Author

Marco La Ferla, Francesca Lessi, Paolo Aretini, Davide Pellegrini, Sara Franceschi, Elena Tantillo, Michele Menicagli, Ivo Marchetti, Claudia Scopelliti, Prospero Civita, Claudia De Angelis, Lucrezia Diodati, Ilaria Bertolini, Manuela Roncella, Liam A. McDonnell, Jacob Hochman, Marzia Del Re, Cristian Scatena, Antonio G. Naccarato, Andrea Fontana, Chiara M. Mazzanti, Roncella, Manuela, Civita, Prospero, Naccarato, Antonio G., Tantillo, Elena, Franceschi, Sara, Aretini, Paolo, Hochman, Jacob, Scatena, Cristian, Lessi, Francesca, Menicagli, Michele, Pellegrini, Davide, Del Re, Marzia, De Angelis, Claudia, La Ferla, Marco, Diodati, Lucrezia, Bertolini, Ilaria, Mcdonnell, Liam A., Scopelliti, Claudia, Marchetti, Ivo, Mazzanti, Chiara M., and Fontana, Andrea

Subjects
0301 basic medicine, Cancer Research, medicine.medical_treatment, Biology, Gene mutation, lcsh:RC254-282, DNA sequencing, 03 medical and health sciences, gene silencing, 0302 clinical medicine, Breast cancer, Trastuzumab, Next generation sequencing, Lc ms ms, Gene expression, medicine, Gene silencing, LC-MS/MS, skin and connective tissue diseases, Trastuzumab resistance, Gene, PI3K/AKT/mTOR pathway, Neoadjuvant therapy, Settore BIO/12 - Biochimica Clinica e Biologia Molecolare Clinica, Original Research, next generation sequencing, business.industry, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, ANKRD44, 030104 developmental biology, Her2+ breast cancer, Oncology, 030220 oncology & carcinogenesis, oncology, Cancer research, Erratum, business, medicine.drug
Abstract

Trastuzumab is an effective therapeutic treatment for Her2-like breast cancer; despite this most of these tumors develop resistance to therapy due to specific gene mutations or alterations in gene expression. Understanding the mechanisms of resistance to Trastuzumab could be a useful tool in order to identify combinations of drugs that elude resistance and allow a better response for the treated patients. Twelve primary biopsies of Her2+/hormone receptor negative (ER-/PgR-) breast cancer patients were selected based on the specific response to neoadjuvant therapy with Trastuzumab and their whole exome was sequenced leading to the identification of 18 informative gene mutations that discriminate patients selectively based on response to treatment. Among these genes, we focused on the study of the ANKRD44 gene to understand its role in the mechanism of resistance to Trastuzumab. The ANKRD44 gene was silenced in Her2-like breast cancer cell line (BT474), obtaining a partially Trastuzumab-resistant breast cancer cell line that constitutively activates the NF-kb protein via the TAK1/AKT pathway. Following this activation an increase in the level of glycolysis in resistant cells is promoted, also confirmed by the up-regulation of the LDHB protein and by an increased TROP2 protein expression, found generally associated with aggressive tumors. These results allow us to consider the ANKRD44 gene as a potential gene involved in Trastuzumab resistance.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results